Neurogene Inc

NASDAQ:NGNEUnited States

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Contact Information

Headquarters

535 W 24Th Street, 5Th FloorNEW YORK, NY, United States 10011

Phone

206-732-2133

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer

Rachel McMinn

President, Chief Financial Officer

Christine Mikail

Senior Vice President, General Counsel

Donna Cochener

Independent Director

Robert Baffi

Independent Director

Cory Freedland